Evidence map›Paper›PMID 35260050›Full record

ReviewCombinatorial chemistry & high throughput screening2023

Ankit Srivastava, Bimal Prasad Jit, Rutumbara Dash, Rishi Srivastava, Sameer Srivastava

Abstract readReview
PubMed Publisher
In one paragraph

Review in Combinatorial chemistry & high throughput screening, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Kaempferol: A Review of Current Evidence of Its Antiviral Potential.International journal of molecular sciences · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Ankit SrivastavaDepartment of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad 211004, India.
Bimal Prasad JitDepartment of Biochemistry, All India Institute of Medical Sciences, New Delhi 110029, India.
Rutumbara DashDepartment of Gastroenterology, All India Institute of Medical Sciences, New Delhi 110029, India.
Rishi SrivastavaDepartment of Practice of Medicine, L R Shah Homeopathy Medical College, Saurashtra University, Rajkot 361162, India.
Sameer SrivastavaDepartment of Biotechnology, Motilal Nehru National Institute of Technology, Allahabad 211004, India.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe recent outbreak of SARS-CoV-2 has received global attention. Due to a lack of recommended treatment regimens, the world faced various limitations resulting in improper management of the disease. Phytomedicines have played a prominent role in the prevention of various epidemics and pandemics in the past.

objectiveHere, we attempt to focus on safe and feasible use of Thuja occidentalis to manage and alleviate the panic of viral respiratory infections, including COVID-19, by strengthening an individual's immunity. The relevant information was collected from the web-based databases PubMed, Google Scholar, and MEDLINE, as well as other internet sources to review the applicability of T. occidentalis as a phytomedicine in managing respiratory infections and strengthening immunity.

conclusionAs important phytomedicine, and antipsychotic, T. occidentalis possesses a plethora of immunological properties that can be used effectively in the management of viral respiratory infections and has the potential to prevent further progression of the disease. Importantly, this could be only a part of the approach for treatment during the current outbreak that should be considered along with other measures.

Indexed as

Antipsychotic AgentsCOVID-19Respiratory Tract InfectionsThujaSARS-CoV-2Antipsychotic AgentsantiviralCOVID-19immunityimmunomodulatoryPhytomedicineThuja occidentalisupper respiratory infection

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.